What Taron Solutions does

Taron Solutions Limited is a Hong Kong-registered biologics contract development and manufacturing organization (CDMO) operating a 'Gene to GMP' service model for biotech and pharmaceutical clients across the Asia-Pacific region, with disclosed presence in Hong Kong, Taiwan, and China. The company positions itself as a partner for organizations seeking to commercialize validated biological drug candidates by bridging the gap between academic/early-stage research and GMP-compliant manufacturing, covering gene modification, stable cell line development, analytical assay development, viral vector production, process development, qualified QC testing, cGMP manufacturing project management, and regulatory submission support (CMC through IND/NDA) across FDA, EMA, NMPA, TGA, and PIC/S frameworks. Its technology stack includes proprietary vector platforms for mammalian and microbial expression with site-specific integration via CRISPR-CAS9, a circRNA synthesis platform that bypasses nucleotide modification and caps/tails, AI-enabled custom culture media design, a viral vector platform spanning AAV, Lentivirus, and VSV, and a proprietary suspension cell line and production media claimed to reduce CMC readiness costs by approximately 30%.

The company operates a hybrid revenue model combining project-based CDMO service fees with catalog sales of recombinant protein products (G-CSF, SARS-CoV-2 RBD, Cadherin-17, B7-H3), custom cell culture media (TS E. coli and TS CHO growth media), and VSV-based pseudoviruses. Pricing on catalog items is published per vial (USD 480-1,200 per 100 µg), while CDMO projects, custom media, and cGMP consulting engagements are quote-based with no public subscription or recurring pricing. Distribution is direct: catalog products are sold through the company website storefront, while CDMO services are sold via enterprise field sales driven primarily by the CEO and management team. The company has secured PIC/S and FDA GMP production licenses, operates a 4,000 sq ft headquarters laboratory in To Kwa Wan alongside a subsidized Science Park lab in Pak Shek Kok, and is constructing a 14,000 sq ft pilot facility with 500L (x2) bioreactor capacity targeted at Phase 2 GMP clinical production. Strategic alliances with Peking University Biologics (for China capacity and NMPA pathway access) and Great Bay Bio (for AI-enabled AlfaCell cell line development), combined with HKD 6M in Hong Kong government grant funding through the HKSTP Incubio program, anchor the operating model, though the firm remains privately held at 1-10 employees with no disclosed revenue.

Name

Taron Solutions

Legal name

Taron Solutions Limited

Website

https://taronsolutions.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Taron Solutions is a Hong Kong-based biologics CDMO providing gene-to-GMP development, manufacturing, and regulatory services for biotech and pharmaceutical clients across Asia-Pacific, supported by proprietary vector, circRNA, and AI-enabled media platforms.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)

akta.pro secondary industries

Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Biologics contract manufacturing
• Cell line development
• Viral vector production
• Process development services
• GMP manufacturing

Headquarters

HQ city

Kowloon City

HQ country

Hong Kong SAR China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Contract Services: Full-scope contract development and manufacturing services covering gene modification, stable cell line development, process development, analytical assay development, GMP manufacturing, and regulatory submission support (CMC/IND/NDA). Revenue is project-based and varies by scope, phase, and scale requirements.
2. Recombinant Protein and Reagent Products: Sale of research-grade recombinant proteins (G-CSF, RBD COVID-19 spike protein, Cadherin-17, B7-H3), VSV pseudoviruses, and custom culture media (E. coli and CHO growth media). Products sold in standard catalog quantities with per-unit pricing.
3. cGMP Facility Consulting: End-to-end consulting services for design, construction, and operation of cGMP manufacturing facilities across biologics, cell and gene therapies, and small molecule manufacturing. Covers technical drawings, cleanroom design, project management, and audit readiness.
4. QC/Analytical Testing Services: Qualified QC testing services for drug characterization during early development and product release testing during preclinical and clinical manufacturing. Includes DNA/protein testing, cell testing, sterility testing, and method validation under USP, EP, CP standards.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Taron Solutions is a contract development and manufacturing organization (CDMO) for biopharmaceuticals that delivers a 'gene to GMP' one-stop service portfolio, including gene modification, stable cell line development, process development, analytical assay development, viral vector development, qualified QC testing, and GMP manufacturing for biologics, antibodies, recombinant proteins, vaccines, and gene/cell therapies. In parallel, the company sells a catalog of recombinant protein products (G-CSF, COVID-19 RBD, Cadherin-17, B7-H3), custom cell culture media, and VSV pseudoviruses via its own website, and offers cGMP facility consulting and CircRNA synthesis services.

Product overview

Taron Solutions is a contract development and manufacturing organization (CDMO) for biologics providing a comprehensive 'gene to GMP' service portfolio. The company's product offerings include recombinant protein products (G-CSF, COVID-19 RBD, Cadherin-17, B7-H3), viral vectors (VSV, AAV, Lentivirus), and custom cell culture media (E. coli and CHO growth media). These are complemented by a full range of CDMO services including gene modification and stable cell line development, analytical and assay development, viral vector development, process development and production, antibody characterization, qualified QC services, cell line storage, GMP manufacturing, and cGMP consultation. The company leverages proprietary vector technology, CRISPR-CAS9, and AI-enhanced custom culture media design to accelerate biologics development for clients.

Differentiator

Problem solved

Functional benefit

Brands

• TS E. coli Growth Medium: Auto-induction growth medium for T7-regulated E. coli strains for protein expression without IPTG addition.
• TS CHO Growth Medium

Products and services

• G-CSF (Granulocyte Colony Stimulating Factor)
• COVID-19 Spike RBD Protein Recombinant SARS-CoV-2 Spike Receptor Binding Domain (RBD) produced in mammalian cells. Contains amino acids 319-532 of the spike protein. Target for neutralizing antibodies and vaccine development. 31-33 kDa, stored at -80°C. Catalog number TSC-002/TSC-003, 100 µg per vial, USD 480 (with His-Tag) or USD 515 (without His-Tag).
• Cadherin-17 Human Cadherin-17 cell adhesion protein expressed in Expi293 cells. 99.1 kDa with 6 His-Tag. Expressed in gastrointestinal tract, involved in epithelial barrier formation and maintenance. Catalog number TSC-004, 100 µg per vial, price upon request.
• B7 Homolog 3 (B7-H3 / CD276) Human B7-H3 (CD276) immune checkpoint protein expressed in Expi293 cells. 73.1 kDa with 6 His-Tag. Modulates T-cell activity and serves as target for immunotherapy research. Catalog number TSC-005, 100 µg per vial, price upon request.
• TS E. coli Growth Medium Auto-induction growth medium for T7-regulated E. coli strains, facilitating protein expression without IPTG addition. Available in powder and liquid formats. 1 kg - 25 kg per order. Catalog number TSC-006, price upon request.
• TS CHO Growth Medium Protein-free, serum-free, chemically-defined medium optimized for CHO cell growth and recombinant protein expression in suspension culture. No animal-derived components. Available in powder and liquid formats. 1 kg - 25 kg per order. Catalog number TSC-007, price upon request.
• VSV Pseudoviruses and Viruses Vesicular Stomatitis Virus (VSV) pseudoviruses and viruses for in vitro and in vivo studies. Includes variants with fluorescent proteins, luciferase markers, and various glycoprotein pseudotyping options (SARS-CoV-2, Lassa, Ebola). Titer >1e8 pfu/ml. Catalog number TSC-008, price upon request.
• CDMO Contract Services (Gene to GMP) Full-scope contract development and manufacturing services covering gene modification, stable cell line development (using proprietary vectors and CRISPR-CAS9 technology for mammalian and microbial expression systems), upstream and downstream process development, comprehensive bioanalytical method development and validation, antibody characterization testing, qualified QC testing (DNA/protein testing, cell testing, sterility testing, method validation under USP/EP/CP standards), and secure cryogenic cell line storage. Services are project-based, quote-priced, and target biotech and biopharma clients.
• GMP Manufacturing Services cGMP manufacturing services for biologics including upstream processing, downstream processing, and aseptic fill-finish operations. Scale-up capability up to 1000L batch production through strategic CDMO partnerships. Compliant with FDA, EMA, NMPA, and PIC/S standards. In-house pilot facility (under construction) targets up to 500L (x2) with potential to expand.
• Viral Vector Development Services Development services for Adeno-Associated Virus (AAV), Lentivirus, and Vesicular Stomatitis Virus (VSV) vectors with high-efficiency single vector or library construction and high-efficiency production/purification for in-vitro, in-vivo, and viral vector therapy screening. Includes CMC readiness support for gene therapy applications.
• CircRNA Synthesis Service Circular RNA synthesis service offering streamlined production without need for caps, tails, or modified nucleotides. Features enhanced purification, extended stability, superior expression compared to linear RNA, seamless formulation, amplified expression, and coding capacity for longer/larger proteins.
• cGMP Facility Consulting End-to-end consulting services for design, construction, and operation of cGMP manufacturing facilities across biologics, cell and gene therapies, and small molecule manufacturing. Covers technical drawings, cleanroom design, project management, and audit readiness.

Quantifiable outcome

• 30% cost reduction in CMC readiness via own suspension cell line, process, and production media
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Great Bay BiocoreTechnology or Integration · 11 November 2025Taron and Great Bay Bio signed a strategic cooperation agreement integrating GBB's AI-enabled Site-Specific Integration (AlfaCell) platform with Taron's industrial-scale development and manufacturing capabilities. The partnership leverages AlfaCell platform, Alfaexpress kit, and related supporting technologies within Taron's facilities to provide services from cell line development and research cell bank establishment to protein purification, quality control, and process development.
• 北大生物 (PKU Biologics / Peking University Biologics)coreStrategic or Co-development Partner · 24 February 2021Long-term strategic partnership between Taron and PKU Biologics (a wholly-owned subsidiary of Sinobioway Medicine, stock code: 002581) for biologics development from early gene development, protein optimization, process development and scale-up to aseptic fill-finish, and US/EU/China regulatory filing support. PKU Biologics has 400,000 sqm production facilities in Anhui with 3x500L and 1x500L pilot production lines, with 8 additional 2000L lines under construction. Taron's international regulatory expertise (FDA, EMA) complements PKU's NMPA expertise.
• Tufts University School of MedicineminorStrategic or Co-development PartnerTaron has an established collaboration with Tufts University School of Medicine, supporting various joint projects in biologics development.
• Hong Kong Science ParkcoreOthersTaron was admitted into the Hong Kong Science Park Incubio program, receiving HKD 6M government grant over 4 years for subsidized laboratory space and PhD hiring. The Science Park provides the physical infrastructure and ecosystem for biotech companies.
• Hong Kong Biotech Multiple Industries Association (HKBMIA)minorOthersTaron was featured in HKBMIA's Life Sciences Stories publication, positioning the company within Hong Kong's biotech ecosystem.
• CDMO Partners in China and TaiwanminorChannel Partner/ Reseller/ DistributorTaron has established collaboration agreements with CDMOs in China and Taiwan, enabling project technology transfer from process development to GMP manufacturing up to 1000L batch production.
• 鸿準精密 / Hon Hai Precision (Foxconn)minorGTM or Marketing PartnerTaron participated in the H.Spectrum+ healthcare accelerator jointly run by Hon Hai Precision and the Yonglin Foundation (永齡基金會), which focuses on precision medicine and diagnostic innovation. Taron was selected from 55 companies to pitch and engage with investors and industry mentors through this program.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• EirGenix: Taiwan-based biosimilars and biologics CDMO offering cell line development, process development, and GMP manufacturing. Directly comparable to Taron's biologics CDMO scope, with similar Asia-Pacific orientation.
• Bora Pharmaceuticals: Taiwan-based CDMO with biologics and complex dosage form manufacturing capabilities, operating GMP facilities in Asia. Comparable to Taron as a regional Asia CDMO pursuing biologics and gene-to-GMP service expansion.
• Pharmaron: China-headquartered CRO/CDMO providing biologics development, cell line engineering, and GMP manufacturing. Directly comparable to Taron in gene-to-GMP biologics CDMO offerings, with much greater scale and geographic reach.
• GenScript ProBio: Biologics CDMO spun out of GenScript offering cell line development, viral vector, plasmid, and GMP manufacturing services. Directly competes with Taron in gene-to-GMP biologics CDMO, particularly across Asia-Pacific and US biotech clients.
• WuXi Biologics: Hong Kong-listed global biologics CDMO offering end-to-end development, cell line, process development, and GMP manufacturing from gene to commercial scale. Directly comparable to Taron on service scope and Hong Kong/China footprint, though materially larger in capacity and headcount.
• Porton Pharma (Cascade Pharm): China-based CDMO offering biologics, viral vector, and cell/gene therapy development and GMP manufacturing. Directly comparable to Taron on biologics and gene therapy CDMO service lines, with deeper regulatory track record and larger facilities.

Broad incumbents

• Lonza: Switzerland-based global CDMO leader with mammalian, microbial, and cell/gene therapy manufacturing capabilities. Operates as a broad incumbent competing across essentially all of Taron's service lines.
• AGC Biologics: Global CDMO offering mammalian and microbial biologics, cell/gene therapy, and viral vector services. Overlaps Taron's biologics and gene therapy CDMO offerings at larger scale and broader geographic reach.
• Samsung Biologics: Korea-based, large-scale biologics CDMO with multi-thousand-liter GMP capacity serving global pharma. Overlaps Taron's biologics CDMO service line as a much larger, established incumbent competitor in the Asia-Pacific market.
• Catalent: Global CDMO with biologics, cell/gene therapy, and viral vector capabilities following the Paragon Biosciences acquisition. Provides broad-incumbent competition across Taron's core gene-to-GMP biologics CDMO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/taron-solutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taron Solutions